Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07457307 · ClinicalTrials.gov registry record · Phase 1
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
A Phase 1 study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07457307 is a Phase 1 study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT07457307, a Phase 1 study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase 1 study to examine the safety and tolerability of biology-guided dose intensified hypofractionated radiation therapy (RT) using MR-Linac for patients with high grade glioma (HGG). Investigators will enroll 20 patients with Grade 3 or 4, IDH wild-type (IDHwt), HGG. Intraoperative assessment of residual tumor burden will be performed at 6 surgical margins (anterior, posterior, superior, inferior, medial, lateral) using FastGlioma. Each margin will be graded on a scale of 0 to 3, with 0 being no tumor, 1 atypical cell, 2 sparse tumor infiltration, and 3 dense tumor infiltration.
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DEVICE MR-Linac System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07457307
The ClinicalTrials.gov registry entry for NCT07457307 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT07457307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07457307 about?
NCT07457307 is a clinical study titled "Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac". This is a phase 1 study to examine the safety and tolerability of biology-guided dose intensified hypofractionated radiation therapy (RT) using MR-Linac for patients with high grade glioma (HGG). Investigators will enroll 20 patients with Grade 3 or 4, IDH wild-type (IDHwt), HGG. Intraoperative asse...
What is the current status of trial NCT07457307?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07457307?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), MR-Linac System (DEVICE).
Who is sponsoring clinical trial NCT07457307?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.